[ Ana Sayfa | Editörler | Danışma Kurulu | Dergi Hakkında | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | E-Posta ]
Fırat Üniversitesi Sağlık Bilimleri Tıp Dergisi
2021, Cilt 35, Sayı 3, Sayfa(lar) 160-167
[ Turkish ] [ Tam Metin ] [ PDF ]
Outcomes of Intra-Vitreal Ranibizumab Mono-Therapy and, Intra-Vitreal Ranibizumab and Intra-Vitreal Triamcinolon Combination Therapy in Diabetic Macular Edema
Gökhan ÖZGÜR1, Berrak ŞEKERYAPAN GEDİZ2, Onur GÖKMEN3
1University of Health Sciences, Samsun Training and Research Hospital, Clinic of Ophthalmology, Samsun, TURKIYE
2University of Health Sciences, Ankara Ulucanlar Eye Training and Research Hospital, Clinic of Ophthalmology, Ankara, TURKIYE
3Van Yüzüncü Yıl University, Faculty of Medicine, Department of Ophthalmology, Van, TURKIYE
Keywords: Diabetic macular edema, ranibizumab, triamcinolon acetat, resistant diabetic macular edema, ıntra-vitreal ınjection

Objective: To investigate the influences of intra-vitreal ranibizumab (IVR) monotherapy and IVR+intra-vitreal triamcinolon (IVTA) combination therapy on visual acuity (VA) and central foveal thickness (CFT) in treatment of diabetic macular edema (DME).

Materials and Methods: 52 eyes of 37 patients who had clinically significant DME were included in the study. All patients were initially administered 0.5 mg/0.05 ml ranibizumab via intra-vitreal route. Following 2 ranibizumab injections unresponsed cases were administered IVR+IVTA combination therapy. Visual acuity and CFT values compared before the injection, and at 1, 3 and 6th months after the injection.

Results: While mean visual acuity was 0.68±0.42 logMAR before the injection. A statistically significant increase was detected in visual acuity at the first and the third months as compared to pre-injection values (0.05). Although visual acuity increased also at the sixth month, the difference between groups was not statistically significant (p>0.05). Mean CFT value was 557.4±157.7 μm before the injection. A statistically significant decrease was detected at the controls of month 1, 3 and 6 as compared to pre-operative CFT (p<0.05). Mean VA was found to be 0,60±0,41 logMar and 0.58±0.38 logMar, respectively when the patients who were applied IVR and IVR+IVTA combination therapy were compared with regard to month 6 results; and mean CFT values were found to be 419.35±205.5 μm and 487.0±215.5 μm, respectively. No statistically significant difference was observed between two groups (p>0.05).

Conclusion: IVR+IVTA combination therapy may be an alternative method in resistant DME cases together with intra-vitreal ranibizumab monotherapy.


[ Turkish ] [ Tam Metin ] [ PDF ]
[ Ana Sayfa | Editörler | Danışma Kurulu | Dergi Hakkında | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | E-Posta ]